Unknown

Dataset Information

0

FOXO1 inactivation induces cisplatin resistance in bladder cancer.


ABSTRACT: We found that FOXO1-shRNA sublines or FOXO1-positive cells co-treated with a FOXO1 inhibitor were significantly more resistant to cisplatin treatment at pharmacological concentrations, compared with respective control sublines or those with mock treatment. Western blot demonstrated considerable increases in the expression levels of a phosphorylated inactive form of FOXO1 (p-FOXO1) in cisplatin-resistant sublines established by long-term culture with low/increasing doses of cisplatin, compared with respective controls. Immunohistochemistry in surgical specimens from patients with muscle-invasive bladder cancer undergoing cisplatin-based neoadjuvant therapy further showed a strong trend to associate between p-FOXO1 positivity and unfavorable response to chemotherapy.

SUBMITTER: Ide H 

PROVIDER: S-EPMC7469822 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications


We found that FOXO1-shRNA sublines or FOXO1-positive cells co-treated with a FOXO1 inhibitor were significantly more resistant to cisplatin treatment at pharmacological concentrations, compared with respective control sublines or those with mock treatment. Western blot demonstrated considerable increases in the expression levels of a phosphorylated inactive form of FOXO1 (p-FOXO1) in cisplatin-resistant sublines established by long-term culture with low/increasing doses of cisplatin, compared wi  ...[more]

Similar Datasets

| S-EPMC10530579 | biostudies-literature
| S-EPMC5862574 | biostudies-literature
| S-EPMC8819945 | biostudies-literature
| S-EPMC7500056 | biostudies-literature
| S-EPMC5439993 | biostudies-literature
2017-04-10 | ST001120 | MetabolomicsWorkbench
| S-EPMC5966259 | biostudies-literature
| S-EPMC5628271 | biostudies-literature
| S-EPMC9760476 | biostudies-literature
| S-EPMC6936234 | biostudies-literature